S100P is a novel marker to identify intraductal papillary mucinous neoplasms

Kohei Nakata, Eishi Nagai, Kenoki Ohuchida, Akifumi Hayashi, Yoshihiro Miyasaka, Shinichi Aishima, Yoshinao Oda, Kazuhiro Mizumoto, Masao Tanaka, Masazumi Tsuneyoshi

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Intraductal papillary mucinous neoplasms of the pancreas are subclassified based on morphological features, and different immunohistochemical profiles have been identified in association with the subtypes. We previously reported that S100P was an early developmental marker of pancreatic carcinogenesis and that there was higher S100P expression in intraductal papillary mucinous neoplasms than in normal pancreatic ductal epithelium. However, there have been no reports on novel diagnostic markers to distinguish intraductal papillary mucinous neoplasm from nonneoplastic lesions. Surgical specimens of intraductal papillary mucinous neoplasm obtained from 105 patients were investigated using immunohistochemistry. S100P expression was not detected in normal pancreatic ductal epithelium but was detected in all intraductal papillary mucinous neoplasm cells (100%) with diffuse nuclear or nuclear/cytoplasmic staining. MUC5AC was also expressed in most of the intraductal papillary mucinous neoplasms (102/105; 97%). Furthermore, S100P was clearly expressed in the invasive component of intraductal papillary mucinous neoplasms (32/32; 100%), including perineural and lymphatic and minimal invasion. On the other hand, MUC5AC was expressed in only 23 cases of 32 invasive components (P < .01). These data suggest that the S100P antibody may be a useful marker for detecting all types of intraductal papillary mucinous neoplasms.

Original languageEnglish
Pages (from-to)824-831
Number of pages8
JournalHuman Pathology
Volume41
Issue number6
DOIs
Publication statusPublished - Jun 1 2010

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this